Aclarion, Inc. — Cyborg Score 4/10

Mixed
Healthcare Technology / Medical Diagnostics

Strategic Profile

Aclarion offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that processes MRS exam data into final spectra and performs degenerative pain biomarker calculations, and NOCIGRAM, which processes results into NOCISCORES on a 0-10 scale. The company also provides NOCISCAN MRS Exam Protocol, a custom software protocol for scanning intervertebral discs which extends the time of a standard lumbar MRI exam, and imaging data transfer products including AMBRA Healthcare.

Cyborg Score Rationale

Aclarion is an early-stage healthcare technology company with innovative MRS-based diagnostic technology for spinal pain assessment. However, the company is unprofitable (negative EPS of -13.61), has a micro-cap valuation (~$7.6M), and faces execution risks in commercializing its clinical platform.

Top Insights

  • Aclarion changed its name from Nocimed, Inc. in December 2021, reflecting a rebranding and strategic evolution
  • Company is focused on degenerative disc disease and discogenic pain, a significant unmet clinical need in spinal care
  • Micro-cap public company with limited institutional support; stock has experienced significant volatility (52-week range: $2.34–$12.03)
  • Early commercialization phase with recent hirings of commercial directors to drive Eastern and Western U.S. expansion

Named Competitors

  • General orthopedic diagnostics — Spinal implants and orthopedic devices
  • MRI and imaging software — Medical imaging platforms and solutions
  • Pain management diagnostics — Pain assessment and management solutions

Recent Developments

  • (May 2026) Participating in 38th Annual ROTH Conference, highlighting key 2026 catalysts and strong balance sheet
  • (May 2026) Announced issuance of U.S. Patent #12,601,803 for machine learning platform analyzing biomarkers
  • (2025) Won 'Rising Star' award at Digital Health Hub Foundation Digital Health Awards at HLTH conference
  • (2026) First patient enrollments announced at two additional CLARITY Trial sites

Open the full interactive Aclarion, Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →